<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the management of advanced cutaneous melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the management of advanced cutaneous melanoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the management of advanced cutaneous melanoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Sosman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H863138373"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most cases of malignant melanoma are diagnosed at an early stage, when surgical excision can be curative. However, patients may present with metastatic disease or develop metastases after their initial definitive treatment.</p><p>Studies have led to the development of immunotherapy using checkpoint inhibitors (the programmed cell death 1 [PD-1] inhibitors [eg, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>], cytotoxic T lymphocyte-associated protein 4 [CTLA-4] inhibitors [eg, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>], and LAG-3 inhibitors [eg, relatlimab]) and targeted therapy (BRAF plus MEK inhibitors). Both checkpoint inhibitor immunotherapy and targeted therapy prolong progression-free and overall survival compared with chemotherapy.</p><p>This topic provides an overview of treatment options for patients with advanced and metastatic cutaneous melanoma, along with their applications in different clinical settings. More detailed discussions of each of the specific treatment options are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/131562.html" rel="external">"Metastatic melanoma: Surgical management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a>.)</p><p></p><p class="headingAnchor" id="H863137073"><span class="h1">TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>Approaches that can provide clinically important benefits for appropriately chosen subsets of patients with metastatic melanoma include surgical metastasectomy, immunotherapy, targeted inhibition of the mitogen-activated protein kinase (MAPK) pathway, and radiation therapy to symptomatic sites of metastases  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Although cytotoxic chemotherapy was widely used prior to the development of checkpoint inhibition immunotherapy and targeted therapies, it does not have an established role for patients with metastatic melanoma.</p><p>The choice and sequencing of these approaches based upon patient-specific factors are discussed below. Additional novel approaches are under active development. Patients should be encouraged to enroll in clinical trials whenever possible. (See <a class="local">'Choice and sequence of therapy'</a> below.)</p><p class="headingAnchor" id="H186311232"><span class="h2">Surgical metastasectomy</span><span class="headingEndMark"> — </span>In patients with one or a very limited number of metastases, surgical excision of all metastatic disease can occasionally produce durable benefit. Surgical resection may be particularly important for patients with brain metastases, in appropriately selected patients. (See  <a class="medical medical_review" href="/d/html/131562.html" rel="external">"Metastatic melanoma: Surgical management"</a> and  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p>Adjuvant systemic therapy may be offered to patients who have undergone definitive resection of all metastatic disease  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Metastatic disease (stage IV)'</a>.)</p><p class="headingAnchor" id="H186311240"><span class="h2">Immunotherapy</span><span class="headingEndMark"> — </span>Checkpoint inhibitor immunotherapy is an important systemic treatment modality for metastatic melanoma  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Responses to immunotherapy may develop slowly, and patients may have a transient worsening of disease before disease stabilizes or tumor regresses; delayed responses are most commonly seen with ipilimumab-containing regimens. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p>Checkpoint immunotherapy inhibition with a programmed cell death 1 (PD-1) inhibitor (<a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) in combination with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> has better efficacy (response rates, progression-free survival) than single-agent anti-PD-1 therapy in patients with advanced melanoma who are candidates for systemic therapy. In a randomized trial, the combination of nivolumab plus ipilimumab also improved survival compared with ipilimumab [<a href="#rid1">1,2</a>]. Combination immunotherapy is also effective as initial therapy in patients with a <em>BRAF</em> V600 mutation. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Nivolumab plus ipilimumab (preferred)'</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Nivolumab plus ipilimumab (preferred)'</a>.)</p><p>Available data suggest that checkpoint inhibitor immunotherapy can also extend treatment-free survival. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Treatment-free survival'</a>.)</p><p>Treatment with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> and, to a lesser extent, the anti-PD-1 antibodies is associated with a variety of clinically significant autoimmune side effects. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p class="headingAnchor" id="H581765521"><span class="h2">Targeted therapy</span></p><p class="headingAnchor" id="H186311247"><span class="h3">BRAF mutations (MAPK pathway)</span><span class="headingEndMark"> — </span>Approximately one-half of cutaneous melanomas have a V600 mutation in the <em>BRAF </em>gene. In combination with downstream MEK, BRAF activates the mitogen-activated protein kinase (MAPK) pathway, resulting in oncogenesis. In a majority of patients with <em>BRAF</em> V600 mutation-positive melanoma, BRAF inhibition produces rapid tumor regression. The addition of MEK inhibition reduces resistance and decreases cutaneous toxicity seen with single-agent BRAF inhibition [<a href="#rid3">3</a>].</p><p>Combined BRAF plus MEK inhibitor therapy has replaced the use of single-agent BRAF inhibitors  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Options include <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, and <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>. Simultaneous inhibition of BRAF and MEK improves response rates and survival compared with BRAF inhibition alone. The rapid tumor regression is especially important for patients with extensive tumor burden and disease-related symptoms. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p>In a retrospective analysis of survival data from two large phase III trials, 34 percent of patients with <em>BRAF</em> V600 mutations treated with the combination of <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> and <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> were alive at five years, and approximately 20 percent were progression free at five years [<a href="#rid4">4</a>]. Lactate dehydrogenase (LDH) appears to be a critical prognostic factor. As an example, 43 percent of patients with normal LDH were alive at five years. Other prognostic factors for improved survival include higher performance status and &lt;3 organ sites with metastases. Further details regarding long-term treatment outcomes for combined BRAF plus MEK inhibitor therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'</a>.)</p><p class="headingAnchor" id="H581765535"><span class="h3">KIT mutations</span><span class="headingEndMark"> — </span>Approximately 10 percent of acral melanomas and up to 5 percent of mucosal melanomas harbor activating mutations in <em>BRAF</em>, and another 15 percent have somatic mutations or amplification of <em>KIT</em>. Only approximately one-third of melanomas with <em>KIT</em> mutations are responsive to targeted therapy, and patients with activating mutations in <em>KIT</em> have had clinically meaningful responses in clinical trials with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. Those with amplifications of <em>KIT </em>have typically not responded to KIT inhibitors. (See  <a class="medical medical_review" href="/d/html/16904.html" rel="external">"Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'KIT mutations (acral and mucosal melanoma)'</a>.)</p><p class="headingAnchor" id="H186311262"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>Radiation therapy may have a palliative role for symptomatic localized areas of disease. Radiation therapy, especially stereotactic radiosurgery, may be particularly important for patients with brain metastases. (See  <a class="medical medical_review" href="/d/html/7614.html" rel="external">"Radiation therapy in the management of melanoma", section on 'Palliative RT'</a> and  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p class="headingAnchor" id="H186311269"><span class="h2">Cytotoxic chemotherapy</span><span class="headingEndMark"> — </span>Cytotoxic chemotherapy (single agent or combination) has not been shown to improve overall survival in patients with advanced melanoma. Response rates are typically less than 20 percent, and median response durations are four to six months. Consequently, the role of chemotherapy (eg, <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>/<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, fotemustine) is limited to patients who have progressed after optimal treatment with other systemic therapy options. (See  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a>.)</p><p class="headingAnchor" id="H179147766"><span class="h1">INITIAL EVALUATION</span><span class="headingEndMark"> — </span>Patients with metastatic melanoma should undergo a detailed evaluation prior to treatment to assess the extent of disease because the likelihood of detecting additional unsuspected lesions is high. This includes pathologic confirmation of metastatic disease, whole body imaging (eg, computed tomography [CT] of the chest, abdomen, and pelvis [and neck for those with primary tumors or nodal involvement of the head and neck region]; positron emission tomography (PET)-CT; and magnetic resonance imaging [MRI] of the brain), and serum lactate dehydrogenase (LDH), which is incorporated into the staging system for melanoma  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>). (See  <a class="medical medical_review" href="/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma"</a> and  <a class="medical medical_review" href="/d/html/7625.html" rel="external">"Imaging studies in melanoma", section on 'Approach to patient imaging based on disease site'</a>.)</p><p>In addition, all patients with advanced cutaneous melanoma should have their tumors rapidly assayed for the presence or absence of a driver mutation at the V600 site in <em>BRAF</em>. For patients in whom a <em>BRAF</em> V600 mutation is not identified, next-generation DNA sequencing (NGS) may be obtained to maximize the chances of identifying other actionable mutations. Patients with an acral or mucosal primary tumor that does not contain a <em>BRAF</em> mutation should have their tumor assessed for the presence of other driver mutations, such as <em>KIT </em>or<em> TRK </em>fusions. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Approach to genetic assay'</a>.)</p><p class="headingAnchor" id="H863137387"><span class="h1">CHOICE AND SEQUENCE OF THERAPY</span><span class="headingEndMark"> — </span>For patients with disseminated metastases, immunotherapy (particularly checkpoint inhibition with anti-programmed cell death 1 [PD-1] antibodies alone or in combination with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) and targeted therapy (inhibiting the mitogen-activated protein kinase [MAPK] pathway) have established clinical roles based upon significant rates of durable remission or prolongation of overall survival  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). </p><p>Whenever possible, the tumor should be assayed for the presence of driver mutations. The presence of such a mutation is an important factor in choosing and sequencing therapies for patients with advanced melanoma. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Assessment of actionable mutations'</a>.)</p><p>In contrast to immunotherapy and targeted therapy, cytotoxic chemotherapy has not been shown to increase survival or to induce durable remissions. Chemotherapy, thus, is generally limited to patients who are not candidates for further treatment with either immunotherapy or targeted therapy and for whom there is no appropriate clinical trial. (See  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a>.)</p><p class="headingAnchor" id="H186311305"><span class="h2">Therapeutic approach</span></p><p class="headingAnchor" id="H2666347165"><span class="h3">Neoadjuvant and adjuvant therapy</span><span class="headingEndMark"> — </span>Immunotherapy and targeted therapies are used in the adjuvant setting for patients at high risk for recurrence following initial surgery. Immunotherapy is also used in the neoadjuvant setting for select patients with high-risk disease prior to definitive surgery  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 2</a>). Further details on the selection of adjuvant and neoadjuvant therapy for cutaneous melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma"</a>.)</p><p>For patients who recur with metastatic disease after initial adjuvant therapy, the approach to systemic therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Prior adjuvant systemic therapy'</a> and  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Prior treatment with single-agent PD-1 inhibitors (including adjuvant therapy)'</a>.)</p><p class="headingAnchor" id="H609823783"><span class="h3">Oligometastatic disease</span><span class="headingEndMark"> — </span>For patients with oligometastatic disease (ie, in only one or a very limited number of sites), the optimal role, timing, and outcome of surgery in the contemporary era of targeted and checkpoint inhibitor immunotherapy remain to be determined. (See  <a class="medical medical_review" href="/d/html/131562.html" rel="external">"Metastatic melanoma: Surgical management"</a>.)</p><p>Patients may be evaluated by a surgical oncologist is indicated to determine whether complete resection of all metastatic disease is feasible as the initial treatment. Although widespread metastatic disease develops in most cases, complete resection of metastatic disease is associated with prolonged survival in select cases. (See <a class="local">'Surgical metastasectomy'</a> above.)</p><p>Adjuvant systemic therapy may be offered to patients who have undergone definitive resection of all metastatic disease. (See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Metastatic disease (stage IV)'</a>.)</p><p>Systemic therapy is indicated for patients in whom surgical metastasectomy is not appropriate. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.) </p><p class="headingAnchor" id="H609823817"><span class="h3">BRAF V600 mutation negative</span><span class="headingEndMark"> — </span>Checkpoint inhibitor immunotherapy is the preferred initial therapy in most patients with metastatic melanoma lacking a driver mutation in <em>BRAF</em> V600  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Options include single-agent PD-1 inhibitors (eg, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) and combination immunotherapy (eg, nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>). Targeted therapy with BRAF plus MEK inhibitors is not indicated in patients without a characteristic <em>BRAF </em>V600 mutation. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Treatment-naive patients'</a>.)</p><p class="headingAnchor" id="H549507"><span class="h3">BRAF V600 mutation positive</span><span class="headingEndMark"> — </span>Immunotherapy is the preferred approach to initial therapy for patients with a <em>BRAF</em> V600 driver mutation as this approach improves overall survival and provides a greater opportunity for long-term treatment-free survival  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Immunotherapy given after progression on a BRAF inhibitor also appears to be relatively less effective than when it is given as initial therapy. Randomized clinical trials evaluating the optimal treatment sequence for patients with <em>BRAF</em>-mutant melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Previously untreated patients'</a>.)</p><p class="headingAnchor" id="H1342355305"><span class="h3">Other molecular alterations</span><span class="headingEndMark"> — </span>Molecular alterations other than <em>BRAF</em> V600 may be present in metastatic melanoma, such as <em>BRAF</em> non-V600 mutations, <em>NRAS</em>, <em>TRK</em> fusions, and <em>KIT</em> mutations, among others. The approach to systemic therapy in these patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Other molecular alterations'</a> and  <a class="medical medical_review" href="/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a> and  <a class="medical medical_review" href="/d/html/138441.html" rel="external">"Treatment of metastatic mucosal melanoma"</a>.)</p><p class="headingAnchor" id="H782153810"><span class="h2">Desmoplastic melanoma</span><span class="headingEndMark"> — </span>Desmoplastic melanoma is a rare variant that comprises less than 5 percent of melanoma cases. Patients with desmoplastic melanoma tend to present with more advanced local disease, but the overall prognosis is better with desmoplastic melanomas compared with other types of melanoma at the same stage. (See  <a class="medical medical_review" href="/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites", section on 'Desmoplastic melanoma'</a>.)</p><p>Patients who do develop disseminated metastases appear to be particularly responsive to checkpoint inhibitor immunotherapy. A multicenter analysis of 1058 patients identified 60 patients with desmoplastic melanoma who were treated with either a PD-1 or programmed cell death ligand 1 (PD-L1) inhibitor (predominantly <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) [<a href="#rid5">5</a>]. Extrapulmonary visceral metastases or elevated lactate dehydrogenase (LDH; M1c disease) was present in 35 cases (58 percent). At a median follow-up of 22 months, objective responses were observed in 42 patients (70 percent), including 19 complete and 23 partial responses. Responses appeared durable, and median progression-free and overall survival had not been reached in this series. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p>The high response to these checkpoint inhibitors may be attributable to the high mutation burden and frequent PD-L1 expression in desmoplastic melanomas [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3118939800"><span class="h2">Acral melanoma</span><span class="headingEndMark"> — </span>Acral melanoma develops on the palms, soles, or nail apparatus. It accounts for approximately 5 percent of all melanomas. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Acral lentiginous melanoma'</a>.)</p><p>In contrast to cutaneous melanoma, acral melanoma has a lower tumor mutational burden, more aggressive biologic behavior, and distinct genetic profile. Both <em>BRAF</em> and <em>KIT</em> variants occur at a low frequency of approximately 10 to 22 percent and 10 to 20 percent, respectively [<a href="#rid6">6-8</a>].</p><p>Acral melanoma is treated similarly to other cutaneous melanomas. However, efficacy of immunotherapy is lower when compared with cutaneous melanoma [<a href="#rid9">9</a>]. In patients with <em>KIT</em> mutations response rates to c-KIT inhibitors such as <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> are around 22 percent [<a href="#rid10">10</a>].</p><p>There are several ongoing investigational approaches to improve the response rate to therapy. These include combinations of immune checkpoint inhibitors, tyrosine kinase inhibitors, vascular endothelial growth factor receptors, and other agents [<a href="#rid11">11</a>]. Patients with metastatic acral melanoma should be considered for clinical trials when possible.</p><p class="headingAnchor" id="H2164502946"><span class="h2">Brain metastases</span><span class="headingEndMark"> — </span>Brain metastases are a frequent complication in patients with advanced regional and metastatic melanoma and are an important cause of both morbidity and mortality. The approach to patients with melanoma brain metastases is rapidly evolving  (<a class="graphic graphic_algorithm graphicRef113993" href="/d/graphic/113993.html" rel="external">algorithm 3</a>) and should be distinguished from the current approach for patients with other types of central nervous system (CNS) metastases. (See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p>Historically, control of CNS lesions was considered the initial priority. Systemic therapy utilizing advances in immunotherapy and targeted therapy has dramatically improved the prognosis for patients with metastatic melanoma. These systemic agents have activity at all sites of disease, including the brain, and the CNS can be considered another site of metastatic disease. The long survival for many patients after receiving immunotherapy and/or targeted therapy has led to approaches to minimize the long-term impact of radiation therapy. These systemic therapy approaches can be integrated into a multidisciplinary management plan  (<a class="graphic graphic_algorithm graphicRef113993" href="/d/graphic/113993.html" rel="external">algorithm 3</a>).</p><p class="headingAnchor" id="H863137233"><span class="h2">Locoregional therapy</span><span class="headingEndMark"> — </span>In selected situations, locoregional therapy may play an important role in the management of patients with advanced melanoma. For patients with cutaneous, subcutaneous, or nodal metastases with only limited visceral involvement, intralesional therapy with <a class="drug drug_general" data-topicid="104964" href="/d/drug information/104964.html" rel="external">talimogene laherparepvec</a> (an attenuated oncolytic herpes simplex virus that contains the granulocyte macrophage colony stimulating factor gene) may be useful. (See  <a class="medical medical_review" href="/d/html/7607.html" rel="external">"Cutaneous melanoma: Management of local recurrence", section on 'Talimogene laherparepvec'</a>.)</p><p class="headingAnchor" id="H1345123000"><span class="h1">PEDIATRIC AND ADOLESCENT PATIENTS</span></p><p class="headingAnchor" id="H2244208948"><span class="h2">Metastatic melanoma</span><span class="headingEndMark"> — </span>There are limited data for the treatment of pediatric patients (age 12 years or older) with unresectable or metastatic melanoma. Our approach is to enroll them in formal clinical trials whenever possible, or to pattern therapy after that in adults. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p>In pediatric patients with unresectable or metastatic melanoma, treatment options that are specifically approved by the US Food and Drug Administration (FDA) include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> [<a href="#rid12">12</a>] and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid13">13</a>], either in combination or as single agents. The use of combination immunotherapy (nivolumab plus ipilimumab) and nivolumab monotherapy in pediatric patients is extrapolated from clinical studies of these regimens in adults with advanced melanoma (CheckMate-067) [<a href="#rid14">14</a>]. Additional pharmacokinetic studies in pediatric patients also demonstrate similar exposure to nivolumab [<a href="#rid15">15</a>] and ipilimumab [<a href="#rid16">16</a>] as that reported in adults. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Treatment-naive patients'</a>.)</p><p>Although single-agent <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> is also approved based on early phase clinical trials of pediatric patients with advanced melanoma [<a href="#rid13">13,16,17</a>], it is less preferred since more effective and well-tolerated agents are available. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Less preferred options'</a>.) </p><p>The FDA has also approved the combination of <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> and <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> for patients with <em>BRAF</em> V600E or V600K melanoma and this includes pediatric patients one year and older [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'</a>.)</p><p class="headingAnchor" id="H334578729"><span class="h2">Resected melanoma</span><span class="headingEndMark"> — </span>The use of adjuvant therapy in pediatric patients with resected melanoma at increased risk for disease recurrence is discussed separately. (See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Pediatric and adolescent patients'</a>.)</p><p class="headingAnchor" id="H179148215"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>The primary objective of surveillance during and after treatment for melanoma is to identify locoregional recurrences that are potentially curable, second primary melanomas, and distant metastatic disease that can be treated with systemic therapy. The approach to surveillance in patients with melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H3163645783"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H863137163"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oligometastatic disease </strong>– For patients with oligometastatic melanoma (ie, metastases limited to one or a limited number of sites), the optimal role, timing, and outcome of surgery in the contemporary era of targeted and checkpoint inhibitor immunotherapy remain to be determined. (See <a class="local">'Oligometastatic disease'</a> above and <a class="local">'Surgical metastasectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients may be evaluated by a surgical oncologist as indicated to determine whether complete resection of all metastatic disease is feasible as the initial treatment. Although widespread metastatic disease develops in most cases, complete resection of metastatic disease is associated with prolonged survival in select cases. (See  <a class="medical medical_review" href="/d/html/131562.html" rel="external">"Metastatic melanoma: Surgical management"</a>.)</p><p></p><p class="bulletIndent2">Surgical resection may be particularly important for select patients with brain metastases  (<a class="graphic graphic_algorithm graphicRef113993" href="/d/graphic/113993.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjuvant systemic therapy may be offered to patients who have undergone definitive resection of all metastatic disease  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Metastatic disease (stage IV)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic therapy is indicated for patients in whom surgical metastasectomy is not appropriate  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic therapy for</strong> <strong>metastatic disease </strong>– The primary options for systemic therapy options in patients with metastatic melanoma are checkpoint inhibitor immunotherapy and targeted therapy against the mitogen-activated protein kinase (MAPK) pathway  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selection of therapy</strong> – The choice of therapy is based upon factors such as the extent of disease, the molecular characteristics of the tumor (eg, presence of a driver mutation in <em>BRAF </em>V600), and patient performance status and comorbidity. (See <a class="local">'Treatment options'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunotherapy</strong> – Options for immunotherapy primarily include a programmed cell death 1 (PD-1) inhibitor alone (eg, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>)), nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 4</a>), a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor, and <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>, a LAG-3 inhibitor  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). (See <a class="local">'Immunotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targeted therapy</strong> – Options for targeted therapy with BRAF plus MEK inhibition include <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, and <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>. (See <a class="local">'BRAF mutations (MAPK pathway)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing for molecular alterations </strong>– Patients with advanced cutaneous melanoma should have their tumors rapidly assessed for the presence of a <em>BRAF</em> V600 mutation to help guide the choice of systemic therapy. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom a <em>BRAF</em> V600 mutation is not identified, we obtain next-generation DNA sequencing (NGS), which maximizes the chances of identifying other actionable mutations. Acral or mucosal melanomas that do not contain<em> a BRAF</em> V600 mutation should also be assessed for the presence of<em> </em>a <em>KIT</em> mutation whenever possible. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Assessment of actionable mutations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF</em></strong><strong> mutation-negative disease </strong>– For patients with treatment-naive <em>BRAF</em> V600 mutation-negative disease  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>), options for systemic therapy include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>), <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>), nivolumab and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 4</a>), and <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>. (See <a class="local">'BRAF V600 mutation negative'</a> above and  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF</em></strong><strong> mutation-positive disease </strong>– For patients with treatment-naive <em>BRAF</em> V600 mutation-positive disease, the optimal sequencing of immunotherapy or molecularly targeted therapy is evolving  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). (See <a class="local">'BRAF V600 mutation positive'</a> above and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In most patients, our general approach is to use immunotherapy as initial therapy, rather than targeted therapies with BRAF plus MEK inhibitors, as this approach improves overall survival and provides a greater opportunity for long-term treatment-free survival. The combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 4</a>) is the preferred initial treatment option in those able to tolerate the potential toxicities of this combination regimen. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Nivolumab plus ipilimumab (preferred)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who progress on (or are ineligible for) immunotherapy are candidates for targeted therapy with a combination of BRAF plus MEK inhibitors. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Prior immunotherapy'</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Ineligible for immunotherapy (targeted therapy)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric patients</strong> – For pediatric patients (age 12 years or older) with unresectable or metastatic melanoma, we offer enrollment in clinical trials whenever possible, or pattern therapy after that in adults. (See <a class="local">'Pediatric and adolescent patients'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23.</a></li><li><a class="nounderline abstract_t">Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019; 381:1535.</a></li><li><a class="nounderline abstract_t">Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 2016; 8:48.</a></li><li><a class="nounderline abstract_t">Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med 2019; 381:626.</a></li><li><a class="nounderline abstract_t">Eroglu Z, Zaretsky JM, Hu-Lieskovan S, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 2018; 553:347.</a></li><li><a class="nounderline abstract_t">Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135.</a></li><li><a class="nounderline abstract_t">Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017; 545:175.</a></li><li><a class="nounderline abstract_t">Newell F, Johansson PA, Wilmott JS, et al. Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. Cancer Discov 2022; 12:2856.</a></li><li><a class="nounderline abstract_t">Klemen ND, Wang M, Rubinstein JC, et al. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Steeb T, Wessely A, Petzold A, et al. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. Eur J Cancer 2021; 157:348.</a></li><li><a class="nounderline abstract_t">Mao L, Lian B, Li C, et al. Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2023; 9:1099.</a></li><li class="breakAll">Nivolumab: US Food and Drug Administration (FDA) Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s119lbl.pdf (Accessed on February 20, 2023).</li><li class="breakAll">Ipilimumab: United States Food and Drug Administration Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125377s129lbl.pdf (Accessed on February 20, 2023).</li><li><a class="nounderline abstract_t">Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377:1345.</a></li><li><a class="nounderline abstract_t">Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21:541.</a></li><li><a class="nounderline abstract_t">Merchant MS, Wright M, Baird K, et al. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res 2016; 22:1364.</a></li><li><a class="nounderline abstract_t">Geoerger B, Bergeron C, Gore L, et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer 2017; 86:358.</a></li><li class="breakAll">Trametinib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s029lbl.pdf (Accessed on September 06, 2023).</li><li class="breakAll">United States (US) Food and Drug Administration (FDA) Prescribing Label for Dabrafenib https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s027lbl.pdf (Accessed on September 06, 2023).</li></ol></div><div id="topicVersionRevision">Topic 85841 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26027431" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562797" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26753005" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31166680" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320474" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : High response rate to PD-1 blockade in desmoplastic melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291983" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Distinct sets of genetic alterations in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28467829" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Whole-genome landscapes of major melanoma subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36098958" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32209601" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34562816" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37261804" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37261804" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37261804" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28889792" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192573" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26534966" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29100190" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
